These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26906133)

  • 1. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma.
    Hronek J; Reed M
    Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
    Sager PT; Balser B; Wolfson J; Nichols J; Pilot R; Jones S; Burris HA
    Cancer Med; 2015 Aug; 4(8):1178-85. PubMed ID: 25914207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romidepsin in the treatment of T-cell lymphoma: profile report.
    Yang LP
    BioDrugs; 2011 Dec; 25(6):393-5. PubMed ID: 22050341
    [No Abstract]   [Full Text] [Related]  

  • 5. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
    Iyer SP; Foss FF
    Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
    Frye R; Myers M; Axelrod KC; Ness EA; Piekarz RL; Bates SE; Booher S
    Clin J Oncol Nurs; 2012 Apr; 16(2):195-204. PubMed ID: 22459529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M
    Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
    Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
    Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
    Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
    Foss F; Horwitz S; Pro B; Prince HM; Sokol L; Balser B; Wolfson J; Coiffier B
    J Hematol Oncol; 2016 Mar; 9():22. PubMed ID: 26965915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
    Zinzani PL; Pellegrini C; Cerciello G; Monaco F; Volpetti S; Peli A; Angelucci E; Corradini P; Cox MC; Guarini A; Musso M; Bresciani P; Amato G; Billio A; Caparrotti G; Figuera A; Nassi L; Gaudio F; Grossi A; Onida F; Merli M; Rigacci L; Argnani L
    Leuk Lymphoma; 2016 Oct; 57(10):2370-4. PubMed ID: 26732313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin for the treatment of cutaneous T-cell lymphoma.
    Campas-Moya C
    Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
    Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
    Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.